Lexaria Completes Dosing in 18-Arm DehydraTECH Study of Oral Retatrutide, Amycretin
LEXX•Lexaria Bioscience completed dosing in its Animal Study #2 evaluating 18 formulation arms of its DehydraTECH platform with next-gen GLP-1 drugs retatrutide and amycretin to assess pharmacokinetics and tolerability. The study compares tablet and capsule forms using compounds like sodium caprate versus SNAC to optimize absorption and reduce side effects.
1. Animal Study #2 Completion
Lexaria Bioscience has completed dosing in its 2026 Animal Study #2 (GLP-1-A26-2), which investigates 18 different DehydraTECH formulation arms to assess oral delivery of next-generation GLP-1 drugs. The study includes both tablet and capsule formats to map pharmacokinetic profiles over a 24-hour period.
2. Next-Generation GLP-1 Drug Profiles
The study evaluates retatrutide, a triple hormone receptor agonist by Eli Lilly that achieved 28.3% average weight loss in Phase 3 trials and 65.3% of participants on 12mg doses reaching BMI below 30, alongside Novo Nordisk’s amycretin. Both compounds are currently available only as weekly injections.
3. Delivery Compound Comparison
Researchers are comparing DehydraTECH formulations using sodium caprate versus the SNAC technology in commercial oral GLP-1 products to determine which enhances absorption and reduces gastrointestinal side effects. Tablet absorption through the stomach is contrasted with capsule-based intestinal uptake to refine delivery strategies.
4. Objectives and Future Implications
Primary goals include demonstrating improved pharmacokinetics and tolerability of oral GLP-1 peptides, while potentially extending DehydraTECH’s patent portfolio with new intellectual property claims on next-generation weight-loss drugs. The self-funded study underscores Lexaria’s strategy to target emerging therapeutics expected to dominate the market over the next decade.
